Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H1, 2019

Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H1, 2019

Summary

the clinical trial report, Dry (Atrophic) Macular Degeneration Global Clinical Trials Review, H1, 2019" provides an overview of Dry (Atrophic) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

List of Tables
List of Figures
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Dry (Atrophic) Macular Degeneration
May 08, 2019: Preclinical studies demonstrate Galimedix Therapeutics investigational compound GAL-101 shows neuroprotective effect from toxic amyloid-beta in dry AMD and glaucoma models
Apr 29, 2019: Catalyst Biosciences & Mosaic Biosciences present preclinical data on Pegylated CB 2782 for the treatment of Dry Age-Related Macular Degeneration
Apr 16, 2019: BioTime to present data from OpRegen phase I/IIa clinical study at the Association for Research in Vision and Ophthalmology Annual Meeting
Mar 06, 2019: Catalyst Biosciences announces poster presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
Feb 26, 2019: Biotime to present new data from OpRegen and vision restoration programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source

List Of Tables


Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries, 2019*
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*

List Of Figures


Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019*
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Dry (Atrophic) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Dry (Atrophic) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Dry (Atrophic) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
GlobalData Methodology

Moderate and Severe Dry Eye Disease Market in China 2023

Dry eye disease is a common eye condition that occurs when the eyes do not produce enough tears or the tears evaporate too quickly. It can cause discomfort, irritation, and

USD 675 View Report

Thioredoxin (Trx or ATL Derived Factor or Surface Associated Sulphydryl Protein or TXN) - Drugs in Development, 2021

Thioredoxin (Trx or ATL Derived Factor or Surface Associated Sulphydryl Protein or TXN) - Drugs in Development, 2021Thioredoxin (Trx or ATL Derived Factor or Surface Associated Sulphydryl Protein or TXN)

USD 3000 View Report

Dry (Atrophic) Macular Degeneration (Ophthalmology) - Drugs in Development, 2021

Dry (Atrophic) Macular Degeneration (Ophthalmology) - Drugs in Development, 2021Dry (Atrophic) Macular Degeneration (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape.The

USD 2000 View Report

Dry (Atrophic) Macular Degeneration Disease - Global Clinical Trials Review, H2, 2020

Dry (Atrophic) Macular Degeneration Disease - Global Clinical Trials Review, H2, 2020clinical trial report, Dry (Atrophic) Macular Degeneration Disease - Global Clinical Trials Review, H2, 2020 provides an overview of

USD 2500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available